| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7862ded04a303ac87332cfdd3807a697 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-675
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-675
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 |
| filingDate |
2018-07-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_03e1dbecdacd58367eabd96d354af4b5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6b95b79e0b45a520c76d9478e44e2406 |
| publicationDate |
2019-01-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2019020634-A2 |
| titleOfInvention |
BETA 2 ADRENERGIC AGONISTS FOR THE TREATMENT OF DISSEMINATED SYSTEMIC LUPUS ERYTHEMATOSUS (LED) AND SYMPTOMS AND MANIFESTATIONS DERIVED FROM LED |
| abstract |
The invention relates to the novel use of beta 2 adrenergic agonists, and more particularly to long-acting beta 2 adrenergic agonists (LABA) or ultra-long-acting beta-adrenergic agonist (ultra-LABA) such as clenbuterol, in the prevention and treatment of systemic lupus erythematosus and symptoms derived from SLE and pathological manifestations. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11331322-B1 |
| priorityDate |
2017-07-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |